NCT07841912Not yet recruiting
Ocular Surface Disease in Glaucoma Patients on Long-Term Therapy
Prevalence and Severity of Ocular Surface Disease Among Adult Patients With Glaucoma on Long-Term Topical Antiglaucoma Medications
Source: ClinicalTrials.gov · Last updated 28 Sept 2026
Brief summary (registry, in English)
This cross-sectional study aims to determine the prevalence and severity of ocular surface disease among adult patients with glaucoma receiving long-term topical antiglaucoma medications.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 55 (estimated)
- First submitted
- 20 Sept 2026
- Start date
- 26 Sept 2026
- Primary completion date
- 26 Sept 2027
- Lead sponsor
- Assiut University
- Diseases
- Glaucoma
- NCT number
- NCT07841912
What you commit to
- Study type: Observational
- Planned participants: 55
- From 26 Sept 2026 to the primary completion date, 26 Sept 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- \- Current use of concomitant topical ocular medication that may affect the ocular surface (e.g., topical cyclosporine)
- Previous ocular surgery within the preceding 6 months
Other illness
- History of corneal surgery or significant ocular trauma affecting the ocular surface
- Active ocular infection or significant active ocular inflammation
- Systemic autoimmune or connective tissue diseases known to affect the ocular surface (e.g., Sjögren's syndrome, rheumatoid arthritis, systemic lupus erythematosus)
Other
- Contact lens wear
- Significant corneal pathology interfering with ocular surface assessment
Who the study is looking for
- \- Age 18 years or older
- Diagnosed glaucoma
- Currently receiving one or more topical antiglaucoma medications
- Duration of topical antiglaucoma treatment ≥6 months
- Written informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.